NDA 007073 · Pfizer
Azulfidine En-Tabs
Sulfasalazine · Oral · Aminosalicylate
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1950
Jun 20, 1950
Approved uses
1
Original approval plus efficacy supplements
Registered trials
104
33 Phase 3, 14 recruiting
FAERS reports
78,454
65,745 serious, 7,496 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 12, 2026.
INDICATIONS AND USAGE Sulfasalazine tablets are indicated: in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and for the prolongation of the remission period between acute attacks of ulcerative colitis
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 20, 1950 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- AZULFIDINE EN-TABS · SULFASALAZINE 500MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
- AZULFIDINE · SULFASALAZINE 500MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sulfasalazine" as an intervention, any sponsor and status, largest first.
- An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core StudiesPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00720798 · 2,067 participants · Start Sep 2005 · Primary completion Apr 2013
Drug: Tocilizumab; Disease-modifying anti-rheumatic drugs and 2 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mesa, Arizona · 295 sites in all
- Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose ReductionPivotal-lookingStatus unknown
Karolinska InstitutetAcademic, hospital or other
NCT01491815 · 812 participants · Start Dec 14, 2012 · Primary completion Jul 2023
Drug: Non-biological DMARD's; Cimzia and 2 more · For: Rheumatoid Arthritis
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 30 sites in all
- Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)Pivotal-lookingCompleted
University of Alabama at BirminghamAcademic, hospital or other
NCT00259610 · 755 participants · Start May 2004 · Primary completion Jun 2009
Drug: methotrexate; sulfasalazine and 2 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama
- A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid ArthritisPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00531817 · 619 participants · Start Oct 2007 · Primary completion Jun 2009
Drug: Tocilizumab; Placebo and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Montgomery, Alabama; Lake Havasu City, Arizona · 157 sites in all
- Study Evaluating Etanercept and Sulphasalazine in Ankylosing SpondylitisPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00247962 · 566 participants · Start Dec 2005 · Primary completion Feb 2008
Drug: etanercept; sulphasalazine (SSZ) · For: Ankylosing Spondylitis
Sites: Heidelberg West, Australia; Shenton Park, Australia; Innsbruck, Austria · 83 sites in all
- To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01709578 · 546 participants · Start Oct 2012 · Primary completion Mar 2015
Drug: Sarilumab; placebo and 4 more · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 196 sites in all
- Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01532648 · 510 participants · Start Jan 27, 2012 · Primary completion Oct 2, 2013
Drug: Budesonide MMX®; Placebo and 1 more · For: Ulcerative Colitis
Sites: Anaheim, California; Lakewood, California; San Diego, California · 114 sites in all
- Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)Pivotal-lookingCompleted
Karolinska InstitutetAcademic, hospital or other
NCT00764725 · 487 participants · Start Dec 2002 · Primary completion Apr 2007
Drug: conventional DMARD combination; MTX plus anti-TNF · For: Rheumatoid Arthritis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective29,490
- rheumatoid arthritis19,666
- pain16,091
- drug intolerance13,852
- arthralgia13,600
- fatigue13,447
- joint swelling12,846
- off label use11,276
- rash11,118
- abdominal discomfort10,166
- contraindicated product administered9,780
- condition aggravated9,702
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 636 |
| 2005 | 614 |
| 2006 | 684 |
| 2007 | 832 |
| 2008 | 843 |
| 2009 | 829 |
| 2010 | 870 |
| 2011 | 1,147 |
| 2012 | 1,441 |
| 2013 | 1,324 |
| 2014 | 1,510 |
| 2015 | 2,401 |
| 2016 | 3,318 |
| 2017 | 5,227 |
| 2018 | 6,253 |
| 2019 | 7,389 |
| 2020 | 11,228 |
| 2021 | 7,186 |
| 2022 | 7,151 |
| 2023 | 5,138 |
| 2024 | 5,753 |
| 2025 | 4,579 |
| 2026 | 2,100 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Azulfidine (Sulfasalazine)
2024 spending
$232K
Beneficiaries
171
532 claims
Per beneficiary
$1,358
$1.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $387,390 |
| 2021 | $579,871 |
| 2022 | $433,431 |
| 2023 | $272,281 |
| 2024 | $232,222 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of pediatric alopecia areata: A systematic review.
Barton VR, Toussi A, Awasthi S, et al. · J Am Acad Dermatol 2022 · Systematic Review, Research Support, N.I.H., Extramural
- Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis.
Chu AWL, Oykhman P, Chu X, et al. · J Allergy Clin Immunol 2025 · Comparative Study, Network Meta-Analysis
- Rheumatoid arthritis.
Walker-Bone K, Farrow S · BMJ Clin Evid 2007 · Systematic Review
- What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines.
Conley B, Bunzli S, Bullen J, et al. · Clin Rheumatol 2023 · Systematic Review
- Meta-analysis and systematic review on Sulfasalazine/5-ASA use during pregnancy: Impact on neonatal and pregnancy outcomes.
Asthana R, Hamandi B, Brnabic A, et al. · Reprod Toxicol 2025 · Meta-Analysis, Systematic Review
- Acupuncture for ulcerative colitis: a systematic review and meta-analysis of randomized clinical trials.
Wang X, Zhao NQ, Sun YX, et al. · BMC Complement Med Ther 2020 · Meta-Analysis, Systematic Review
Sponsor: Pfizer · Also marketed as Azulfidine
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.